Geratherm Medical AI Stock Analysis
Want to see DE:GME full AI Analyst Report?
Geratherm Medical (GME) AI Stock Analysis
Geratherm Medical
(XETRA:GME)
Overall score reflects weakening operating performance (losses and volatile/weak revenue) despite a conservative balance sheet and still-positive (but declining) free cash flow. Technicals add pressure as the price is below key moving averages with a negative MACD, while valuation is supported mainly by the ~5% dividend yield.
Geratherm Medical (GME) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 11.22M
- Dividend Yield
- 4.85%
- Average Volume (3M)
- 1,106
- Price to Earnings (P/E)
- -14.8
- Beta (1Y)
- 0.52
- Revenue Growth
- 1.58%
- EPS Growth
- -148.73%
- Country
- Germany
- Employees
- 136
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Geratherm Medical Business Overview & Revenue Model
Company Description
Geratherm Medical AG, a German-based medical technology enterprise, organizes its operations across four primary divisions: Healthcare Diagnostic, Respiratory, Cardio/Stroke, and Medical Warming Systems. The Healthcare Diagnostic unit offers a range...
How the Company Makes Money
Geratherm Medical makes money primarily by selling medical devices and associated health products to distributors, pharmacies, retailers, and other healthcare-channel customers. Revenue is generated through (1) product sales of Geratherm-branded meas...
Geratherm Medical Financial Statement Overview
Summary
Financials are mixed. The balance sheet is a strength with low leverage (TTM debt-to-equity ~0.11) and solid equity vs. assets, but profitability has deteriorated back into losses (TTM net margin ~-5.8%) alongside sharply negative reported revenue growth (-219%). Cash flow is positive (TTM FCF ~€0.4m) but weakening (FCF growth ~-46%) and conversion is uneven.
Income Statement
38NegativeBalance Sheet
72PositiveCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.70M | 14.86M | 20.43M | 20.96M | 25.85M | 24.64M |
| Gross Profit | 9.82M | 2.37M | 12.78M | 6.27M | 6.38M | 16.32M |
| EBITDA | 217.53K | -154.63K | 2.95M | 4.20M | 3.37M | 2.20M |
| Net Income | -854.16K | -818.99K | 705.17K | 1.11M | 1.02M | 122.23K |
Balance Sheet | ||||||
| Total Assets | 25.54M | 26.00M | 28.54M | 35.72M | 38.38M | 34.56M |
| Cash, Cash Equivalents and Short-Term Investments | 8.81M | 9.26M | 9.64M | 7.74M | 10.89M | 6.47M |
| Total Debt | 2.19M | 2.48M | 3.28M | 7.23M | 9.29M | 9.32M |
| Total Liabilities | 6.62M | 6.55M | 7.71M | 13.11M | 16.15M | 15.93M |
| Stockholders Equity | 19.38M | 19.66M | 21.02M | 22.33M | 22.34M | 18.52M |
Cash Flow | ||||||
| Free Cash Flow | 419.00K | 1.22M | 1.23M | -212.00K | -133.00K | -353.00K |
| Operating Cash Flow | 618.00K | 1.39M | 1.87M | 1.43M | 2.61M | 917.00K |
| Investing Cash Flow | -532.00K | -328.00K | 3.82M | -2.09M | -767.00K | 3,000 |
| Financing Cash Flow | -1.24M | -1.31M | -2.69M | -3.09M | 4.35M | -3.52M |
Geratherm Medical Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:GME, the sentiment is Negative. The current price of 2.06 is below the 20-day moving average (MA) of 2.14, below the 50-day MA of 2.20, and below the 200-day MA of 2.52, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 43.20 is Neutral, neither overbought nor oversold. The STOCH value of 43.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:GME.
Geratherm Medical Peers Comparison
Overall Rating
DE:SHL77Outperform
DE:DRW363.7Neutral
DE:M3V55Neutral
DE:SBS54Neutral
DE:GME51Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 77Outperform | EUR 48.31B | 22.14 | 11.72% | 2.28% | 1.09% | 3.52% | |
| 64Neutral | EUR 1.93B | 13.16 | 10.20% | 1.91% | 5.06% | 40.18% | |
| 55Neutral | EUR 38.22M | 27.63 | 7.77% | 4.52% | -6.92% | -67.82% | |
| 54Neutral | EUR 332.47M | -7.84 | -18.69% | 2.19% | ― | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | EUR 11.22M | -14.76 | -4.38% | 4.85% | 1.58% | -148.73% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:GME | Geratherm Medical | 2.06 | -1.14 | -35.56% | |
| DE:DRW3 | Draegerwerk AG & Co. KGaA | 119.00 | 52.43 | 78.75% | |
| DE:M3V | MeVis Medical Solutions | 21.00 | -2.90 | -12.13% | |
| DE:SBS | STRATEC Biomedical | 27.35 | 8.04 | 41.62% | |
| DE:SHL | Siemens Healthineers | 43.84 | 3.52 | 8.73% | |
| DE:E8X | elexxion AG | 0.01 | -0.13 | -90.71% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
